30 Leading Biosimilars Companies Shaping Innovation and Market Growth to 2035

Discover the top 30 companies driving innovation in the Biosimilars market. This in-depth analysis explores competitive advantages, transformative trends, and key players poised to influence global pharmaceuticals and chronic disease management through 2035. Access the comprehensive market research report here for further insights.

The Biosimilars market is evolving rapidly, guided by the expiration of blockbuster biologic patents and an urgent global shift toward cost-effective healthcare solutions. In this dynamic environment, the following 30 industry leaders stand out for their technical innovations, strategic focus, and pivotal roles in oncology, immunology, and metabolic health worldwide.

1. SANDOZ GROUP AG

Sandoz Group AG maintains a commanding presence as a pure-play leader in the biosimilars sector, focusing on high-quality follow-on biologics that expand patient access. The company is actively conducting trials for next-generation assets, including an ocrelizumab biosimilar, to maintain its edge in the competitive European and North American markets.

2. PFIZER INC.

Pfizer Inc. leverages its massive global infrastructure to drive biosimilar adoption, particularly in oncology where it has seen operational growth as high as 76%. For 2026, Pfizer is emphasizing a "Pivot to Growth" strategy, balancing its innovative pipeline with robust biosimilar competition to counter revenue impacts from loss of exclusivity on older products.

3. AMGEN INC.

Amgen Inc. has successfully integrated its heritage as a biologics innovator into a powerful biosimilar portfolio that has generated over $13 billion in sales since 2018. The company is currently focused on navigating the upcoming patent expiration of Xgeva and managing competition in the denosumab market to sustain its $37 billion+ revenue targets for 2026.

4. CELLTRION INC.

Celltrion Inc. is aggressively expanding its manufacturing capabilities, recently opening its first U.S. facility to ensure supply chain resilience and eliminate trade risks. The company aims to commercialize 41 biosimilar products by 2038, targeting an addressable market exceeding KRW 400 trillion across autoimmune and oncology therapeutic areas.

5. BIOCON

Biocon Biologics, a subsidiary of Biocon Ltd., is a fully integrated global player serving over 6.3 million patients in 120+ countries. With 10 commercialized biosimilars and a pipeline of 20+ assets, the company is leveraging its "lab to market" capabilities to drive 25% year-on-year revenue growth in its biologics segment.

6. DR. REDDY’S LABORATORIES LTD.

Dr. Reddy’s Laboratories is focusing on strategic market entry timing, with a planned U.S. launch for its Abatacept biosimilar by the end of 2026. The firm is also building R&D capacity around the broader GLP-1 class and semaglutide to counter pricing pressures in its base generics business.

7. ELI LILLY AND COMPANY

Eli Lilly and Company is diversifying its immunology and metabolic portfolios through significant investments, including a $1.93 billion collaboration to develop new autoimmune therapies. While a major innovator, its manufacturing agreements—such as the one with Celltrion—highlight its strategic role in the broader biologics and biosimilar supply chain.

8. TEVA PHARMACEUTICAL INDUSTRIES LTD.

Teva Pharmaceutical Industries boasts one of the industry's largest biosimilar portfolios, with plans to launch six new products through 2027. Under its "Pivot to Growth" strategy, Teva expects to double its biosimilar revenue from 2024 levels, utilizing its commercial strength in both Europe and the U.S..

9. FRESENIUS KABI AG

Fresenius Kabi AG is advancing its "Vision 2026" framework, which prioritizes the broadening of its Biopharma segment alongside MedTech and Nutrition. The company focuses on digitalization and intelligent technology to enhance the production of affordable therapies for chronically and critically ill patients.

10. STADA ARZNEIMITTEL AG

STADA Arzneimittel AG specializes in specialty pharmaceuticals and biosimilars, maintaining a strong European footprint through strategic partnerships and a focused portfolio in oncology and immunology.

11. BOEHRINGER INGELHEIM INTERNATIONAL GMBH

Boehringer Ingelheim is recognized for its high-quality manufacturing standards and its commitment to the adalimumab market, providing reliable alternatives for chronic inflammatory diseases.

12. SAMSUNG BIOLOGICS

Samsung Biologics (through Samsung Bioepis) is a major force in the U.S. market, having launched 11 biosimilars as of early 2026. The company is pioneering 20 biosimilars by 2030, including complex candidates for oncology and ophthalmology.

13. AMNEAL PHARMACEUTICALS LLC

Amneal Pharmaceuticals is rapidly expanding its biosimilar presence in the U.S., focusing on oncology and specialty injectables to drive long-term growth and diversify its generics-heavy portfolio.

14. COHERUS BIOSCIENCES

Coherus BioSciences remains a key contender in the U.S. biosimilars market, emphasizing cost-effective versions of leading biologics in oncology and immunology to improve patient access.

15. BIO-THERA SOLUTIONS

Bio-Thera Solutions is a significant player in the Asia-Pacific region and is expanding globally through agreements to commercialize biosimilars like dupilumab in Latin America.

16. APROGEN

Aprogen is known for its proprietary R&D and manufacturing technologies, focusing on developing high-quality biosimilars for the global market from its base in South Korea.

17. SHANGHAI HENLIUS BIOTECH, INC.

Shanghai Henlius Biotech is a leader in the Chinese biosimilars market, with a growing portfolio of monoclonal antibodies that are increasingly gaining traction in international regulatory pathways.

18. ALVOTECH

Alvotech specializes in the development and manufacture of biosimilars, utilizing a fully integrated platform and strategic partnerships with companies like Teva to commercialize products globally.

19. AMEGA BIOTECH

Amega Biotech focuses on the Latin American market, providing affordable biologic treatments for oncology and nephrology through its regional manufacturing and distribution networks.

20. BIOCAD

Biocad is a leading Russian biotechnology company with an extensive biosimilar pipeline, including a Phase III ocrelizumab candidate aimed at treating multiple sclerosis.

21. PROBIOMED S.A. DE C.V.

Probiomed is a pioneer in Mexico's biotech sector, focusing on the production of high-tech biosimilars to treat chronic-degenerative diseases at a lower cost.

22. FUJIFILM KYOWA KIRIN BIOLOGICS CO., LTD.

This joint venture combines FUJIFILM's advanced production technology with Kyowa Kirin’s R&D expertise to deliver high-quality biosimilars in oncology and immunology.

23. POLPHARMA BIOLOGICS GROUP

Polpharma Biologics is a European powerhouse in biosimilar development, recently entering licensing agreements to commercialize guselkumab biosimilars in the MENA region.

24. NEUCLONE

NeuClone leverages its proprietary technology platform to develop high-quality, low-cost biosimilars, focusing on monoclonal antibodies for global therapeutic use.

25. XENTRIA

Xentria is a biopharmaceutical company focused on unmet medical needs, utilizing biosimilar development as a core pillar of its strategy to provide affordable biologics.

26. YL BIOLOGICS

YL Biologics, a joint venture in Japan, focuses on the development and commercialization of biosimilars specifically tailored for the Japanese regulatory environment and patient needs.

27. KASHIV BIOSCIENCES, LLC

Kashiv BioSciences is an innovation-led company with a focus on complex generics and biosimilars, aiming to provide high-quality affordable medicines through advanced delivery systems.

28. NANOGEN PHARMACEUTICAL BIOTECHNOLOGY JSC

Nanogen is a leading biotechnology company in Vietnam, focusing on biosimilar production for various indications, including hepatitis and oncology, for the Southeast Asian market.

29. SYNERMORE BIOLOGICS (SUZHOU) CO., LTD.

Synermore Biologics focuses on the development of monoclonal antibodies and biosimilars, utilizing its Suzhou-based facilities to address global healthcare challenges.

30. CURATEQ BIOLOGICS PVT. LTD.

Curateq Biologics, a subsidiary of Aurobindo Pharma, is focused on creating a robust pipeline of biosimilars in oncology and immunology to capitalize on global patent expiries.

Conclusion: Unlock the Full Biosimilars Market Intelligence

The Biosimilars market’s future is shaped by a blend of technological convergence, regulatory evolution, and strategic adaptation among its leading companies. To explore in-depth trends, segmentation insights, and actionable recommendations for sustainable growth, access the full Biosimilars Market by Drug Class (mAbs (Adalimumab, Infliximab, Rituximab, Trastuzumab), GCSF, Insulin, Anticoagulant, rhGH, Teriparatide, GLP-1), Indication (Oncology, Autoimmune, Diabetes, Obesity), Competitive Landscape, Region - Global Forecast to 2035 report now.